Elixinol Global Sales Rise to A$8 Million in Q2 | CashCropToday
0 Shares 406 Views

Elixinol Global Sales Rise to A$8 Million in Q2

July 30, 2018
406 Views

Elixinol Global (ASX: EXL) (OTC: ELLXF), an Australian based hemp Cannabidiol (CBD) product manufacturing and distribution company, announced their Q2 financial results today. Elixinol has impressively reported sales of A$8.0 million, which is a reported growth of 111% from last year.

Elixinol sells a variety of premium CBD products in the form of cosmetics, topical’s, tinctures, capsules, and pet products. The company’s headquarters is located out of Australia but, currently has distribution networks setup in the United States, Europe, South America, and Japan, where just this year Elixinol was accepted as the first CBD company to distribute and market in the country.

Elixinol has also recently joint ventured with Kersey Ag to complete the cultivation of high- yielding CBD industrial hemp in Colorado. Their newly founded company, Northern Colorado High Plains Producers completed its first planting of hemp in April 2018. Elixinol plans to cultivate industrial hemp in Colorado in the hopes of establishing a extraction and manufacturing facility for their product line in the United States.

The company is currently trading at $1.41AUD per share and has a market cap of 146.159 million dollars.

You may be interested

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon
Market Watch
269 views
Market Watch
269 views

Global Hemp Group Announces Harvest Update on their CBD Hemp Farm in Scio Oregon

Editor - November 27, 2018

Vancouver, BC -- (November 27, 2018) -- GLOBAL HEMP GROUP INC. (“GHG” or the “Company”) (CSE: GHG / OTC: GBHPF / FRANKFURT: GHG) and its joint venture…

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition
Global
191 views
Global
191 views

Wayland Group Enters UK Cannabis Market with Theros Pharma Acquisition

Editor - November 26, 2018

Wayland Group (CSE:WAYL) (OTCQB:MRRCF) has announced this morning that their company has entered into an agreement to acquire 51% of UK company Theros Pharma Ltd. The Wayland Group…

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials
Manufacturing
189 views
Manufacturing
189 views

GW Pharma’s CBD Pharmaceutical, Epidiolex, Shows Results in Lowering Seizures in Clinical Trials

Editor - November 26, 2018

GW Pharmaceuticals (Nasdaq: GWPH) has announced this morning that their company has completed a double-blind, placebo-controlled Phase 3 clinical trial for its Cannabidiol (CBD) derived product EPIDIOLEX®.…

Leave a Comment

Your email address will not be published.

Most from this category

%d bloggers like this: